reported that the independent prognostic capability of the CRP/Alb ratio is noteworthy in individuals with stage III and IV pancreatic carcinoma, but evidently not in patients with pancreatic cancer clinically staged as stage I or II (44). The gene discussed is CRP; the disease is familial pancreatic carcinoma.